PND49 An Assessment of Real-World Healthcare Provider Experiences with Insomnia Medications Focusing on Suvorexant in the United States (US)
This study evaluated healthcare provider (HCP) experiences with suvorexant and other pharmacotherapies (for example, benzodiazepines, non-benzodiazepines sleep agents such as zolpidem, eszopiclone, zaleplon, or antidepressants) in a real-world setting. (Source: Value in Health)
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: M. Carlyle, Z. Qureshi, C. Martin, J. White, R. Khandker Source Type: research
Prevalence of and factors associated with acute withdrawal symptoms after 24 weeks of eszopiclone treatment in patients with chronic insomnia: a prospective, interventional study
Although long-term use of benzodiazepines and benzodiazepine receptor agonists (BZDs) has been associated with an increased risk of dependence, the incidence, details of clinical manifestations, and triggering... (Source: BMC Psychiatry)
Source: BMC Psychiatry - April 14, 2021 Category: Psychiatry Authors: Yuichi Inoue, Yoshikazu Takaesu and Michinori Koebis Tags: Research article Source Type: research
Evaluation of serious bleeding signals during concomitant use of clopidogrel and hypnotic drugs
CONCLUSIONS: While we could not confirm or refute previously identified DDI signals, numerically elevated RRRs for serious bleeding with several clopidogrel + hypnotic pairs warrant further examination.PMID:33845372 | DOI:10.1016/j.biopha.2021.111559 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 12, 2021 Category: Drugs & Pharmacology Authors: Thanh Phuong Pham Nguyen Colleen M Brensinger Warren B Bilker Sean Hennessy Charles E Leonard Source Type: research
Evaluation of serious bleeding signals during concomitant use of clopidogrel and hypnotic drugs
CONCLUSIONS: While we could not confirm or refute previously identified DDI signals, numerically elevated RRRs for serious bleeding with several clopidogrel + hypnotic pairs warrant further examination.PMID:33845372 | DOI:10.1016/j.biopha.2021.111559 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 12, 2021 Category: Drugs & Pharmacology Authors: Thanh Phuong Pham Nguyen Colleen M Brensinger Warren B Bilker Sean Hennessy Charles E Leonard Source Type: research
Efficacy of Electroconvulsive Therapy for Neuropathic Pain Comorbid with Major Depression.
We report a case of a 41-year-old male with postinjury neuropathic pain comorbid with major depression in which electroconvulsive therapy (ECT) was effective in relieving both neuropathic pain and major depression. A total of 12 sessions of bilateral ECT were performed using a Thymatron® (Somatics LLC; Lake Bluff, IL). After ECT, the patient was subsequently maintained on paroxetine, eszopiclone (2 mg/day), and alprazolam. There was no relapse for at least one year after the last ECT. This case indicates that ECT might be an alternative treatment for major depression associated with chronic neuropathic pain after trauma...
Source: Case Reports in Psychiatry - December 30, 2020 Category: Psychiatry Tags: Case Rep Psychiatry Source Type: research
Lemborexant (Dayvigo) for Insomnia
Date: June 29, 2020
Issue #:
1601Summary:
The FDA has approved lemborexant (Dayvigo– Eisai),
an orexin receptor antagonist, for treatment of sleep-onset
and/or sleep-maintenance insomnia in adults. It
is the second orexin receptor antagonist to be approved
for this indication; suvorexant (Belsomra) was the first. (Source: The Medical Letter)
Source: The Medical Letter - June 22, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Ambien Antihistamines Ativan Belsomra bromazepam Dayvigo Doral Doxepin Edluar estazolam Eszopiclone Flurazepam Halcion Imovane insomnia lemborexant Lorazepam Lunesta melatonin Mogadon nitrazepam Oxazepam Quazepa Source Type: research
Development of a novel tandem mass spectrometry method for the quantification of eszopiclone without interference from 2-amino-5-chloropyridine and application in a pharmacokinetic study of rat
Publication date: Available online 23 May 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Ruichen Liu, Dongke Liu, Jin Zhang, Hengchang Zang, Yanhui Gao (Source: Journal of Pharmaceutical and Biomedical Analysis)
Source: Journal of Pharmaceutical and Biomedical Analysis - May 25, 2020 Category: Drugs & Pharmacology Source Type: research
[ASAP] Solubility Measurement and Modeling of Eszopiclone in Four Binary Solvents
Journal of Chemical& Engineering DataDOI: 10.1021/acs.jced.0c00047 (Source: Journal of Chemical and Engineering Data)
Source: Journal of Chemical and Engineering Data - April 23, 2020 Category: Chemistry Authors: Shujia Sun ‡, Yanfang Wu‡, Xuan Yao, Shunping Yang, and Yan Liu* Source Type: research
Reintroduction of quazepam: an update on comparative hypnotic and adverse effects
Insomnia is a prevalent disorder that affects over one-third of the U.S. population to varying degrees and is highly disruptive towards quality of life. Pharmacological treatments for insomnia include benzodiazepines (BZs) and the non-BZ ‘Z-drugs’ (zolpidem, zaleplon, eszopiclone, zopiclone), which are amongst the most widely prescribed medications. Yet, these agents can produce adverse effects such as tolerance to the hypnotic effect, rebound insomnia, next-day residual drowsiness, as well as amnesia and complex behaviours such as sleep-walking, sleep-eating and sleep-driving. Quazepam, one of the five BZ approved for...
Source: International Clinical Psychopharmacology - September 27, 2019 Category: Psychiatry Tags: Review Articles Source Type: research
Common Insomnia Drugs Receive Black Box Warning
A black box warning about the risk of serious injury and potential death as a result of sleepwalking and other complex sleep behaviors has been added to the labeling of the sedative–hypnotic drugs zolpidem, zaleplon, and eszopiclone.Serious adverse effects from use of these drugs to treat insomnia include falls with serious injuries, fatal falls, fatal motor vehicle accidents, self-injury, and suicidal attempts and suicides, among others.NPs should not prescribe these drugs to patients who have a history of complex sleep behaviors after taking antiinsomnia drugs. The drugs should be discontinued if patients experience ad...
Source: AJN - July 30, 2019 Category: Nursing Tags: Drug Watch Source Type: research
